Galectin Therapeutics Reports Q1 2026 Results and Business Update

What Happened
Galectin Therapeutics, Inc. (GALT) filed an 8‑K on May 15, 2026, to announce its results of operations and financial condition for the three months ended March 31, 2026, and to provide a business update. The company incorporated by reference a press release dated May 15, 2026 (attached as Exhibit 99.1) that contains the detailed results and statements about ongoing operations. The filing notes that forward‑looking statements in the press release are subject to risks and uncertainties and refers investors to the company’s Form 10‑K for the fiscal year ended December 31, 2025 for additional risk factors.

Key Details

• Filing date: May 15, 2026; reporting period: three months ended March 31, 2026.
• The press release with the results is attached as Exhibit 99.1 and is incorporated by reference into the 8‑K.
• The company states that forward‑looking statements are subject to the Private Securities Litigation Reform Act safe harbor and points investors to risk factors in its 2025 Form 10‑K.
• Item references: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).

Why It Matters
This 8‑K signals Galectin is publicly disclosing its latest quarterly operational and financial position and giving investors a business update. Investors should read the attached press release for the specific financial numbers and operational highlights, and review the company’s 2025 Form 10‑K for risk factors that could affect future results. The filing itself does not amend prior disclosures but reiterates that forward‑looking statements are subject to material uncertainty.